By using β-glucan in combination with anti-tumor mAbs activating complements, the coat of iC3b on tumor cells triggers CR3 dependent cytotoxicity by monocytes, granulocytes, and NK cells [45]. The gene discussed is CRIPTO3; the disease is neoplasm.